EUVIMEDEUVIMED entdecken
Crossref

L26/O-244 Managing ‘‘difficult’’ patients with assistance of IVM

M. De Vos

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.242 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von M. De Vos.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In-vitro maturation (IVM) of oocytes has historically been considered a niche assisted reproductive technology due to lower efficiency compared with conventional assisted reproductive technologies. However, recent advances in culture systems, laboratory techniques, and patient selection have led to a renewed interest in its clinical application. Rather than serving as a universal alternative to ovarian stimulation, IVM is increasingly recognized as a targeted strategy for specific patient populations in whom conventional approaches are either unsafe, ineffective, or impractical. This presentation will provide an updated overview of the current status of IVM, highlighting recent improvements in maturation protocols and clinical outcomes. Particular emphasis will be placed on its role in women with severe polycystic ovary syndrome (PCOS), where IVM offers a safe and effective approach that reduces hormonal burden, simplifies monitoring, and eliminates the risk of ovarian hyperstimulation syndrome. The role of IVM in fertility preservation will also be discussed, especially in oncology patients who require urgent treatment and cannot undergo ovarian stimulation, or in those with a high risk of malignant ovarian involvement where ovarian tissue cryopreservation may not be safe. In this context, IVM enables the retrieval and maturation of immature oocytes without delaying cancer therapy. In addition, the presentation will address the potential utility of IVM in the rare conditions of gonadotropin-resistant ovary syndrome, where conventional stimulation fails and IVM may represent the only viable assisted reproductive option using autologous oocytes. For each of these indications, illustrative clinical case examples will be presented to demonstrate practical application, patient selection, and outcomes. In conclusion, IVM should be considered a precision tool in reproductive medicine, offering distinct advantages in carefully selected challenging cases. Its integration into clinical practice depends not only on technological advances but also on appropriate patient stratification.

Zitieren

APA

Vos, M. D. (2026). L26/O-244 Managing ‘‘difficult’’ patients with assistance of IVM. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.242

Vancouver

Vos MD. L26/O-244 Managing ‘‘difficult’’ patients with assistance of IVM. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.242

BibTeX
@article{Vos2026,
  author = {Vos, M. De},
  title = {L26/O-244 Managing ‘‘difficult’’ patients with assistance of IVM},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.242}
}
Kostenlos starten →